Lytgobi (lisocabtagene maraleucel) Patient Guide
Lytgobi is a CAR-T cell therapy made from a patient’s own genetically modified immune cells. It is used to treat adults with relapsed or refractory multiple myeloma after other cancer treatments have stopped working.
Lytgobi is a one-time infusion given at a specialized cancer treatment center, not a daily pill. It can cause serious immune reactions, so close monitoring and prompt medical care are essential.
Key facts at a glance
- RxNorm
- 2628196
- Generic
- Lytgobi
- Class
- brand-name
- Brands
- —
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- —
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy